Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$62.3M
8 rounds on record
Latest round
$8M
Venture round · Aug 2024 · 2 yr ago
Team
5
US Form 5500 (plan participants) · Dec 2025 · -17% in a year
Backers
1
Sound Bioventures
The money's age
Long since its last round
25 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 12, 2024
Raised a round Venture round $8M · Pulse 2.0
Dec 17, 2021
Raised a round Venture round $25.8M · SEC Form D
Dec 17, 2021
Raised a round Venture round $25.8M · SEC Form D
Feb 16, 2021
Took on debt financing $2.2M · SEC Form D
Apr 17, 2020
Raised a round Venture round $2M · SEC Form D
Jul 31, 2019
Raised a round Venture round $750k · SEC Form D
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Aug 2024 | $8M | — | Pulse 2.0 |
| Debt Financing | Jul 2024 | $19M | — | SEC Form D |
| Debt Financing | Jul 2024 | $19M | — | SEC Form D |
| Venture round | Dec 2021 | $25.8M | — | SEC Form D |
| Venture round | Dec 2021 | $25.8M | — | SEC Form D |
| Debt Financing | Feb 2021 | $2.2M | — | SEC Form D |
| Venture round | Apr 2020 | $2M | — | SEC Form D |
| Venture round | Jul 2019 | $750k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Artax Biopharma, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Damia Tormo Ph.D. MBMExecutive Officer, DirectorSEC Form D
Robert Armstrong Ph.D.Executive Officer, DirectorSEC Form D
Joseph LobackiExecutive Officer, DirectorSEC Form D
Robert ArmstrongExecutive Officer, DirectorSEC Form D
Maria NicholExecutive OfficerSEC Form D
Joe SuarezExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Sound Bioventures Similar startupsby what they do, their industry and backers
Decoding Human T issue Biology to C reate Revolutionary T herapeutics. TRexBio is developing immunoregulatory medicines designed to restore…
— Reshaping treatment for Functional Mitral Regurgitation (FMR) Transcatheter Leaflet Restoration (TLR) system is engineered to work in…
About Us Aarki provides an industry leading mobile performance advertising solution powered by great people and technology Aarki was built…
GravitHy awards CAP INGELEC EPC contract for Fos-sur-Mer electrical substation. GravitHy selects Danieli for its 2 million tonnes Direct…
Aniah’s Smart Network Analysis reduces the number of false errors by a factor of 100-1000x.
DexMat produces Galvorn: the advanced carbon material that delivers a multi-property advantage — conductivity, strength, light weight, and…
News
Report
Shifting Focus in Autoimmune Diseases
Artax Biopharma's CEO Rob Armstrong explains recent shifts in autoimmune R&D before discussing his leadership style.
Read more
Report
Evaluation of AX-158, a first-in-class Nck modulator, in patients with mild-to-moderate plaque psoriasis
D. Scott Batty, Jr., MD1, Christopher VanDeusen, PhD1, Sandra Garcet, PhD2, James G. Krueger, MD PhD2 EADVPoster2025-ARTAX_FINALXDownload
Read more
Report
Restoring Immune Balance: The Next Wave Of T Cell-Targeted Therapeutics
Nektar's success with Rezpeg highlights a shift toward T cell-targeted autoimmune therapies aimed at restoring immune balance rather than suppressing inflammation. Companies like Revolo, CUE Biopharma, and Artax are pioneering distinct approaches, showing
Read more
Report
Resetting the Immune System with Artax Biopharma's Dr. Rob Armstrong
In this episode of the Xtalks Life Science Podcast, host Ayesha Rashid speaks with Rob Armstrong, PhD, CEO of Artax Biopharma, a company pioneering a novel class of oral small molecule drugs known as Nck modulators to treat autoimmune diseases. Unlike tra
Read more
Report
Nck Modulators Target Root Causes of Autoimmune Disorders with Rob Armstrong Artax Biopharma
Rob Armstrong, CEO of Artax Biopharma, highlights the basic mechanism of action of Nck modulators and how they differ from traditional immunosuppressant drugs to treat autoimmune diseases. Taking this adjustable thermostat approach aims to modulate the im
Read more
Report
Report
Artax Biopharma presents Phase 2a results for oral Nck modulator AX-158 in late-breaking session at the Society for Investigative Dermatology 2025 Annual Meeting
First small molecule to modulate the fundamental mechanism ofT cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related biomarkers in line with PASI improvements in Phase 2a in patients with ps
Read more
Report
AX-158 Proof-of-Mechanism Safety Study: Evaluating a Novel T cell Receptor (TCR)
Signal Modulator in Patients with Mild-to-Moderate Plaque Psoriasis SIDPoster2025-VANDEUSEN_LB1150Download
Read more
Report
Show more news
People
Damia Tormo Ph.D. MBM
Executive Officer, Director
Robert Armstrong Ph.D.
Executive Officer, Director
Joseph Lobacki
Executive Officer, Director
Robert Armstrong
Executive Officer, Director
Maria Nichol
Executive Officer
Joe Suarez
Executive Officer
Alan Walts
Director
Gino Santini
Director
Javier Garcia
Director
Damia Tormo Ph.D.
Director
Damia Tormo
Director
Raj Parekh
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Cambridge
United States
HQ
Broadway
United States
Regional office
Get in touch
1 Broadway, Cambridge, MA 02142, USA
Financials
Total raised
$102.5M
Latest round
Venture - Series Unknown
Funding rounds
8
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2024 | $8M | Details |
| Debt Financing | 2024 | $19M | Details |
| Debt Financing | 2024 | $19M | Details |
| Venture - Series Unknown | 2021 | $25.8M | Details |
| Venture - Series Unknown | 2021 | $25.8M | Details |
| Debt Financing | 2021 | $2.2M | Details |
| Venture - Series Unknown | 2020 | $2M | Details |
| Venture - Series Unknown | 2019 | $750k | Details |